GPC4 and Insulin resistance: The depletion of glypican-4 reduces insulin signaling, whereas the overexpression of wild-type glypican-4 enhances the insulin-mediated phosphorylation of ERK and AKT (Ussar et al., 2012), indicating its potential role as a target for the treatment of insulin resistance (Mitchell, 2012).